Alpha Cognition Inc. (NASDAQ:ACOG – Get Free Report) Director Robert James Wills bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were purchased at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the purchase, the director directly owned 32,241 shares of the company’s stock, valued at approximately $310,158.42. This trade represents a 44.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Alpha Cognition Price Performance
Shares of NASDAQ:ACOG opened at $9.75 on Tuesday. Alpha Cognition Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $10.14. The firm’s 50 day moving average price is $8.13 and its 200 day moving average price is $6.69. The stock has a market cap of $212.34 million, a price-to-earnings ratio of -8.86 and a beta of 2.31.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $4.38 million. On average, equities analysts anticipate that Alpha Cognition Inc. will post -1.38 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
ACOG has been the topic of several recent analyst reports. B. Riley Financial assumed coverage on Alpha Cognition in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price on the stock. Raymond James Financial initiated coverage on Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 price objective for the company. Craig Hallum reiterated a “buy” rating and issued a $17.00 price objective on shares of Alpha Cognition in a report on Friday, August 14th. HC Wainwright raised their target price on Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Alpha Cognition has an average rating of “Buy” and an average price target of $18.00.
Get Our Latest Stock Analysis on ACOG
Alpha Cognition Company Profile
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
